Last reviewed · How we verify
TILMANOCEPT
At a glance
| Generic name | TILMANOCEPT |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2014 |
Approved indications
Common side effects
- Injection site irritation
- Injection site pain
Key clinical trials
- Repurposing Tilmanocept for Cardiac Sarcoidosis (PHASE2)
- Immunomodulatory Effects of PCSK9 Inhibition
- Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial (PHASE2)
- An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) (PHASE1)
- Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA (PHASE3)
- Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept (PHASE2)
- Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA (PHASE2)
- Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TILMANOCEPT CI brief — competitive landscape report
- TILMANOCEPT updates RSS · CI watch RSS